SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Nielsen Søren L.) "

Sökning: WFRF:(Nielsen Søren L.)

  • Resultat 1-10 av 16
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Madin, Joshua S., et al. (författare)
  • A synthesis of bacterial and archaeal phenotypic trait data
  • 2020
  • Ingår i: Scientific data. - : Springer Science and Business Media LLC. - 2052-4463. ; 7:1
  • Tidskriftsartikel (refereegranskat)abstract
    • A synthesis of phenotypic and quantitative genomic traits is provided for bacteria and archaea, in the form of a scripted, reproducible workflow that standardizes and merges 26 sources. The resulting unified dataset covers 14 phenotypic traits, 5 quantitative genomic traits, and 4 environmental characteristics for approximately 170,000 strain-level and 15,000 species-aggregated records. It spans all habitats including soils, marine and fresh waters and sediments, host-associated and thermal. Trait data can find use in clarifying major dimensions of ecological strategy variation across species. They can also be used in conjunction with species and abundance sampling to characterize trait mixtures in communities and responses of traits along environmental gradients.
  •  
2.
  • Rasmussen, Morten, et al. (författare)
  • Ancient human genome sequence of an extinct Palaeo-Eskimo
  • 2010
  • Ingår i: Nature. - : Springer Science and Business Media LLC. - 0028-0836 .- 1476-4687. ; 463:7282, s. 757-762
  • Tidskriftsartikel (refereegranskat)abstract
    • We report here the genome sequence of an ancient human. Obtained from ∼4,000-year-old permafrost-preserved hair, the genome represents a male individual from the first known culture to settle in Greenland. Sequenced to an average depth of 20×, we recover 79% of the diploid genome, an amount close to the practical limit of current sequencing technologies. We identify 353,151 high-confidence single-nucleotide polymorphisms (SNPs), of which 6.8% have not been reported previously. We estimate raw read contamination to be no higher than 0.8%. We use functional SNP assessment to assign possible phenotypic characteristics of the individual that belonged to a culture whose location has yielded only trace human remains. We compare the high-confidence SNPs to those of contemporary populations to find the populations most closely related to the individual. This provides evidence for a migration from Siberia into the New World some 5,500 years ago, independent of that giving rise to the modern Native Americans and Inuit.
  •  
3.
  • Barbateskovic, Marija, et al. (författare)
  • A new tool to assess Clinical Diversity In Meta-analyses (CDIM) of interventions
  • 2021
  • Ingår i: Journal of Clinical Epidemiology. - : Elsevier BV. - 0895-4356 .- 1878-5921. ; 135, s. 29-41
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: To develop and validate Clinical Diversity In Meta-analyses (CDIM), a new tool for assessing clinical diversity between trials in meta-analyses of interventions. Study design and setting: The development of CDIM was based on consensus work informed by empirical literature and expertise. We drafted the CDIM tool, refined it, and validated CDIM for interrater scale reliability and agreement in three groups. Results: CDIM measures clinical diversity on a scale that includes four domains with 11 items overall: setting (time of conduct/country development status/units type); population (age, sex, patient inclusion criteria/baseline disease severity, comorbidities); interventions (intervention intensity/strength/duration of intervention, timing, control intervention, cointerventions); and outcome (definition of outcome, timing of outcome assessment). The CDIM is completed in two steps: first two authors independently assess clinical diversity in the four domains. Second, after agreeing upon scores of individual items a consensus score is achieved. Interrater scale reliability and agreement ranged from moderate to almost perfect depending on the type of raters. Conclusion: CDIM is the first tool developed for assessing clinical diversity in meta-analyses of interventions. We found CDIM to be a reliable tool for assessing clinical diversity among trials in meta-analysis.
  •  
4.
  • Gunst, Jesper D., et al. (författare)
  • Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial
  • 2021
  • Ingår i: eClinicalMedicine. - : Elsevier. - 2589-5370. ; 35
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The trans-membrane protease serine 2 (TMPRSS2) is essential for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry and infection. Efficacy and safety of TMPRSS2 inhibitors in patients with coronavirus disease 2019 (Covid-19) have not been evaluated in randomized trials.Methods: We conducted an investigator-initiated, double-blind, randomized, placebo-controlled multicenter trial in patients hospitalized with confirmed SARS-CoV-2 infection from April 4, to December 31, 2020. Within 48 h of admission, participants were randomly assigned in a 2:1 ratio to receive the TMPRSS2 inhibitor camostat mesilate 200 mg three times daily for 5 days or placebo. The primary outcome was time to discharge or clinical improvement measured as ≥2 points improvement on a 7-point ordinal scale. Other outcomes included 30-day mortality, safety and change in oropharyngeal viral load. ClinicalTrials.gov Identifier: NCT04321096. EudraCT Number: 2020-001,200-42.Findings: 137 patients were assigned to receive camostat mesilate and 68 to placebo. Median time to clinical improvement was 5 days (interquartile range [IQR], 3 to 7) in the camostat group and 5 days (IQR, 2 to 10) in the placebo group (P = 0·31). The hazard ratio for 30-day mortality in the camostat compared with the placebo group was 0·82 (95% confidence interval [CI], 0·24 to 2·79; P = 0·75). The frequency of adverse events was similar in the two groups. Median change in viral load from baseline to day 5 in the camostat group was -0·22 log10 copies/mL (p <0·05) and -0·82 log10 in the placebo group (P <0·05).Interpretation: Under this protocol, camostat mesilate treatment was not associated with increased adverse events during hospitalization for Covid-19 and did not affect time to clinical improvement, progression to ICU admission or mortality.
  •  
5.
  • Sahin, Cagla, et al. (författare)
  • Structural basis for dityrosine-mediated inhibition of alpha-synuclein fibrillation
  • Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
    • α-synuclein (aSyn) is a small intrinsically disordered protein which can self-assemble into highly organized β-sheet structures that are found to accumulate in plaques in the brain of Parkinson’s Disease patients. Oxidative stress has been shown to be important for aSyn and its self-assembly. Here we characterize the molecular and structural effects that mild oxidation has on aSyn monomer and its aggregation. Using a combination of biophysical methods, SAXS and native ion mobility mass spectrometry, we find that oxidation leads to formation of intramolecular dityrosine cross-linkages that reduce aSyn’s size by a factor of √2. MD simulations support our experimental results showing a stable and compact aSyn conformation that prevents self-assembly and amyloid formation by steric hindrance, suggesting an important role of mild oxidation in preventing amyloid formation. 
  •  
6.
  • Burisch, Johan, et al. (författare)
  • Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort : an ECCO-EpiCom Study
  • 2015
  • Ingår i: Inflammatory Bowel Diseases. - 1078-0998 .- 1536-4844. ; 21:1, s. 121-131
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe.METHODS: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (&OV0556;) using the Danish Health Costs Register.RESULTS: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was &OV0556;5,408,174 (investigations: &OV0556;2,042,990 [38%], surgery: &OV0556;1,427,648 [26%], biologicals: &OV0556;781,089 [14%], and standard treatment: &OV0556;1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations &OV0556;1803 (&OV0556;2160) (P = 0.44), surgery &OV0556;11,489 (&OV0556;13,973) (P = 0.14), standard treatment &OV0556;1027 (&OV0556;824) (P = 0.51), and biologicals &OV0556;7376 (&OV0556;8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations &OV0556;1189 (&OV0556;1518) (P < 0.01), surgery &OV0556;18,414 (&OV0556;12,395) (P = 0.18), standard treatment &OV0556;896 (&OV0556;798) (P < 0.05), and biologicals &OV0556;5681 (&OV0556;72) (P = 0.51).CONCLUSIONS: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15% of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.
  •  
7.
  • Citterio, Michele, et al. (författare)
  • Automatic weather stations for basic and applied glaciological research
  • 2015
  • Ingår i: Geological Survey of Denmark and Greenland Bulletin. - 1811-4598 .- 1604-8156. ; 33, s. 69-72
  • Tidskriftsartikel (refereegranskat)abstract
    • Since the early 1980s, the Geological Survey of Denmark and Greenland (GEUS) glaciology group has developed automatic weather stations (AWSs) and operated them on the Greenland ice sheet and on local glaciers to support glaciological research and monitoring projects (e.g. Olesen & Braithwaite 1989; Ahlstrøm et al. 2008). GEUS has also operated AWSs in connection with consultancy services in relation to mining and hydropower pre-feasibility studies (Colgan et al. 2015). Over the years, the design of the AWS has evolved, partly due to technological advances and partly due to lessons learned in the field. At the same time, we have kept the initial goal in focus: long-term, year-round accurate recording of ice ablation, snow depth and the physical parameters that determine the energy budget of glacierised surfaces. GEUS has an extensive record operating AWSs in the harsh Arctic environment of the diverse ablation areas of the Greenland ice sheet, glaciers and ice caps [...].The GEUS AWS model in use now is a reliable tool that is adapted to the environmental and logistical conditions of polar regions. It has a proven record of more than 150 stationyears of deployment in Greenland since its introduction in 2007–2008, and a success rate of c. 90% defined as the fraction of months with more than 80% valid air-temperature measurements over the total deployment time of the 25 stations in the field. The rest of this paper focuses on the technical aspects of the GEUS AWS, and provides an overview of its design and capabilities.
  •  
8.
  • Fenton, Thomas M., et al. (författare)
  • Immune Profiling of Human Gut-Associated Lymphoid Tissue Identifies a Role for Isolated Lymphoid Follicles in Priming of Region-Specific Immunity
  • 2020
  • Ingår i: Immunity. - : Elsevier BV. - 1074-7613. ; 52:3, s. 557-570
  • Tidskriftsartikel (refereegranskat)abstract
    • The intestine contains some of the most diverse and complex immune compartments in the body. Here we describe a method for isolating human gut-associated lymphoid tissues (GALTs) that allows unprecedented profiling of the adaptive immune system in submucosal and mucosal isolated lymphoid follicles (SM-ILFs and M-ILFs, respectively) as well as in GALT-free intestinal lamina propria (LP). SM-ILF and M-ILF showed distinct patterns of distribution along the length of the intestine, were linked to the systemic circulation through MAdCAM-1+ high endothelial venules and efferent lymphatics, and had immune profiles consistent with immune-inductive sites. IgA sequencing analysis indicated that human ILFs are sites where intestinal adaptive immune responses are initiated in an anatomically restricted manner. Our findings position ILFs as key inductive hubs for regional immunity in the human intestine, and the methods presented will allow future assessment of these compartments in health and disease.
  •  
9.
  • Hindy, George, et al. (författare)
  • Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
  • 2022
  • Ingår i: Journal of Clinical Investigation. - 0021-9738. ; 132:24, s. 1-14
  • Tidskriftsartikel (refereegranskat)abstract
    • People with kidney disease are disproportionately affected by atherosclerosis for unclear reasons. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived mediator of kidney disease, levels of which are strongly associated with cardiovascular outcomes. We assessed suPAR’s pathogenic involvement in atherosclerosis using epidemiologic, genetic, and experimental approaches. We found serum suPAR levels to be predictive of coronary artery calcification and cardiovascular events in 5,406 participants without known coronary disease. In a genome-wide association meta-analysis including over 25,000 individuals, we identified a missense variant in the plasminogen activator, urokinase receptor (PLAUR) gene (rs4760), confirmed experimentally to lead to higher suPAR levels. Mendelian randomization analysis in the UK Biobank using rs4760 indicated a causal association between genetically predicted suPAR levels and atherosclerotic phenotypes. In an experimental model of atherosclerosis, proprotein convertase subtilisin/kexin–9 (Pcsk9) transfection in mice overexpressing suPAR (suPARTg) led to substantially increased atherosclerotic plaques with necrotic cores and macrophage infiltration compared with those in WT mice, despite similar cholesterol levels. Prior to induction of atherosclerosis, aortas of suPARTg mice excreted higher levels of CCL2 and had higher monocyte counts compared with WT aortas. Aortic and circulating suPARTg monocytes exhibited a proinflammatory profile and enhanced chemotaxis. These findings characterize suPAR as a pathogenic factor for atherosclerosis acting at least partially through modulation of monocyte function.
  •  
10.
  • Holm, Lars, et al. (författare)
  • An exploration of the methods to determine the protein-specific synthesis and breakdown rates in vivo in humans.
  • 2019
  • Ingår i: Physiological Reports. - : John Wiley & Sons. - 2051-817X. ; 7:17
  • Tidskriftsartikel (refereegranskat)abstract
    • The present study explores the methods to determine human in vivo protein-specific myofibrillar and collagenous connective tissue protein fractional synthesis and breakdown rates. We found that in human myofibrillar proteins, the protein-bound tracer disappearance method to determine the protein fractional breakdown rate (FBR) (via 2 H2 O ingestion, endogenous labeling of 2 H-alanine that is incorporated into proteins, and FBR quantified by its disappearance from these proteins) has a comparable intrasubject reproducibility (range: 0.09-53.5%) as the established direct-essential amino acid, here L-ring-13 C6 -phenylalanine, incorporation method to determine the muscle protein fractional synthesis rate (FSR) (range: 2.8-56.2%). Further, the determination of the protein breakdown in a protein structure with complex post-translational processing and maturation, exemplified by human tendon tissue, was not achieved in this experimentation, but more investigation is encouraged to reveal the possibility. Finally, we found that muscle protein FBR measured with an essential amino acid tracer prelabeling is inappropriate presumably because of significant and prolonged intracellular recycling, which also may become a significant limitation for determination of the myofibrillar FSR when repeated infusion trials are completed in the same participants.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 16
Typ av publikation
tidskriftsartikel (15)
annan publikation (1)
Typ av innehåll
refereegranskat (15)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Brunak, Søren (4)
Erikstrup, Christian (3)
Christiansen, Gunna (2)
Pedersen, Jan Skov (2)
Otzen, Daniel E. (2)
Sahin, Cagla (2)
visa fler...
Österlund, Nicklas (2)
Ilag, Leopold L (2)
Landreh, Michael (2)
Banasik, Karina (2)
Engström, Gunnar (1)
Fröbert, Ole, 1964- (1)
Costeira-Paulo, Joan ... (1)
Marklund, Erik G (1)
Costeira-Paulo, Joan ... (1)
Marklund, Erik, Tekn ... (1)
Melander, Olle (1)
Burisch, Johan (1)
Magro, Fernando (1)
Halfvarson, Jonas, 1 ... (1)
Mason, Christopher E ... (1)
Agace, William W. (1)
Möller, Ian M (1)
Wang, Jun (1)
Olsson, Martin L (1)
Rasmussen, Morten (1)
Cajander, Sara, 1980 ... (1)
Orho-Melander, Marju (1)
Wang, Yong (1)
Wang, Hui (1)
Zhao, Jing (1)
Lotta, Luca A. (1)
Hjalgrim, Henrik (1)
Storry, Jill R (1)
Hansen, Thomas F. (1)
Almer, Sven (1)
Meldgaard, Morten (1)
Nielsen, Rasmus (1)
Willerslev, Eske (1)
Orlando, Ludovic (1)
Johansson-Lindbom, B ... (1)
Sicheritz-Ponten, Th ... (1)
Gilbert, M. Thomas P ... (1)
Krogh, Anders (1)
Danko, David (1)
Storgaard, Merete (1)
Andersen, Vibeke (1)
Blomstrand, Eva (1)
Vieira-Silva, Sara (1)
Perner, Anders (1)
visa färre...
Lärosäte
Uppsala universitet (6)
Lunds universitet (4)
Karolinska Institutet (3)
Stockholms universitet (2)
Örebro universitet (2)
Umeå universitet (1)
visa fler...
Chalmers tekniska högskola (1)
Gymnastik- och idrottshögskolan (1)
visa färre...
Språk
Engelska (16)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (8)
Medicin och hälsovetenskap (8)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy